In Vitro and In Vivo Activity against Staphylococcus aureus and Pharmacokinetic Evaluation of a Novel Pleuromutilin Candidate
ACS Infectious Diseases · 11.09.2026 · 12 (9) · 3230-3240
DOI: 10.1021/acsinfecdis.6c00558 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 24.08.2026. Verfasst von Feifei Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricu…. Hauptthemen laut MEDLINE: Pleuromutilins, Staphylococcus aureus, Staphylococcal Infections. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Staphylococcus aureus infections pose a serious threat to public health, exacerbated by antimicrobial resistance and the limited pipeline of novel agents. Pleuromutilin, a natural antibiotic, provides a promising scaffold for developing new antibacterial agents via structural modification. To overcome the poor druggability of the lead compound amphenmulin (APM), we designed and synthesized a novel derivative, Pleuro2–4. This derivative exhibited potent in vitro activity against S. aureus, with efficacy comparable to valnemulin and superior to tiamulin. Molecular docking suggested favorable interactions with the bacterial ribosome, while scanning electron microscopy revealed morphological alterations associated with impaired cell division. Pharmacokinetics in mice revealed dose-dependent oral bioavailability (21.28% to 70.13%) and rapid metabolism to APM. Pleuro2–4 significantly reduced bacterial loads in a dose-dependent manner and alleviated histopathological damage in a neutropenic murine thigh infection model. Collectively, Pleuro2–4 exhibited improved oral exposure and bioavailability with potent antibacterial efficacy and favorable pharmacokinetic properties, warranting further pharmacokinetic/pharmacodynamic and efficacy studies in target species.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou510642, China.
- National Laboratory of Safety Evaluation (Environmental Assessment) of Veterinary Drugs, South China Agricultural University, Guangzhou510642, China.
- National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, South China Agricultural University, Guangzhou510642, China.
ORCID-Profile: Youzhi Tang, Zhenling Zeng
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Zhao, F., Luo, X., Zhang, T., Huang, H., Zhu, Y., Lin, W., Wu, S., Tang, Y., & Zeng, Z. (2026). In Vitro and In Vivo Activity against Staphylococcus aureus and Pharmacokinetic Evaluation of a Novel Pleuromutilin Candidate. ACS Infectious Diseases, 12(9), 3230-3240. https://doi.org/10.1021/acsinfecdis.6c00558
Vancouver
Zhao F, Luo X, Zhang T, Huang H, Zhu Y, Lin W, et al. In Vitro and In Vivo Activity against Staphylococcus aureus and Pharmacokinetic Evaluation of a Novel Pleuromutilin Candidate. ACS Infectious Diseases. 2026;12(9):3230-3240. doi:10.1021/acsinfecdis.6c00558
BibTeX
@article{Zhao2026,
author = {Zhao, Feifei and Luo, Xinyue and Zhang, Tingting and Huang, Honghao and Zhu, Yizhen and Lin, Wanxin and Wu, Sujuan and Tang, Youzhi and Zeng, Zhenling},
title = {In Vitro and In Vivo Activity against Staphylococcus aureus and Pharmacokinetic Evaluation of a Novel Pleuromutilin Candidate},
journal = {ACS Infectious Diseases},
year = {2026},
volume = {12},
number = {9},
pages = {3230--3240},
doi = {10.1021/acsinfecdis.6c00558}
}
EUVIMED